Dorman Followwill Net Worth

The estimated Net Worth of Dorman Followwill is at least $302 mil dollars as of 16 December 2020. Mr. Followwill owns over 1,000 units of Sorrento Therapeutics Inc stock worth over $21 and over the last 7 years he sold SRNE stock worth over $7,140. In addition, he makes $294,493 as Lead Independent Director at Sorrento Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Followwill SRNE stock SEC Form 4 insiders trading

Dorman has made over 1 trades of the Sorrento Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 1,000 units of SRNE stock worth $7,140 on 16 December 2020.

The largest trade he's ever made was selling 1,000 units of Sorrento Therapeutics Inc stock on 16 December 2020 worth over $7,140. On average, Dorman trades about 167 units every 0 days since 2017. As of 16 December 2020 he still owns at least 2,130 units of Sorrento Therapeutics Inc stock.

You can see the complete history of Mr. Followwill stock trades at the bottom of the page.

Dorman Followwill biography

Dorman Followwill serves as Lead Independent Director of the Company. Mr. Followwill has been Senior Partner, Transformational Health at Frost & Sullivan, a business consulting firm involved in market research and analysis, growth strategy consulting and corporate training across multiple industries, since 2016. Prior to that time, he served in various roles at Frost & Sullivan, including Partner on the Executive Committee managing the P&L of the business in Europe, Israel and Africa, and Partner overseeing the Healthcare and Life Sciences business in North America, since initially joining Frost & Sullivan to help found the Consulting practice in January 1988. Mr. Followwill has more than 30 years of organizational leadership and management consulting experience, having worked on hundreds of consulting projects across all major regions and across multiple industry sectors, each project focused around the strategic imperative of growth.

What is the salary of Dorman Followwill?

As the Lead Independent Director of Sorrento Therapeutics Inc, the total compensation of Dorman Followwill at Sorrento Therapeutics Inc is $294,493. There are 6 executives at Sorrento Therapeutics Inc getting paid more, with Jaisim Shah having the highest compensation of $10,971,100.

How old is Dorman Followwill?

Dorman Followwill is 57, he's been the Lead Independent Director of Sorrento Therapeutics Inc since 2020. There are 4 older and 6 younger executives at Sorrento Therapeutics Inc. The oldest executive at Sorrento Therapeutics Inc is Dr. Michael A. Royal, 67, who is the SVP & Chief Medical Officer.

What's Dorman Followwill's mailing address?

Dorman's mailing address filed with the SEC is C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTORS PLACE, SAN DIEGO, CA, 92121.

Insiders trading at Sorrento Therapeutics Inc

Over the last 15 years, insiders at Sorrento Therapeutics Inc have traded over $17,198,839 worth of Sorrento Therapeutics Inc stock and bought 10,353,437 units worth $10,703,222 . The most active insiders traders include Jane Ph D Hsiao, Edgar Lee y Patrick Chan Soon Shiong Fa.... On average, Sorrento Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $2,947. The most recent stock trade was executed by Henry Ji on 7 September 2022, trading 88,888 units of SRNE stock currently worth $179,554.

What does Sorrento Therapeutics Inc do?

sorrento therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical car-t therapies targeting solid tumors.

Complete history of Mr. Followwill stock trades at Sorrento Therapeutics Inc

Sorrento Therapeutics Inc executives and stock owners

Sorrento Therapeutics Inc executives and other stock owners filed with the SEC include:

• Jaisim Shah,
  Director
• Henry Ji,
  Chairman of the Board, President, Chief Executive Officer, Co-Founder
• Dr. Henry H. Ji Ph.D.,
  Chairman, Pres & CEO
• Najjam Asghar,
  Sr. VP & CFO
• Kim Janda,
  Director
• Yue Wu,
  Independent Director
• Dorman Followwill,
  Lead Independent Director
• David Lemus,
  Independent Director
• Robin Smith,
  Independent Director
• Edgar Lee,
  Independent Director
• Najjam Asghar,
  Chief Financial Officer
• William J. Farley,
  VP of Sales & Bus. Devel.
• Dr. Robert D. Allen Ph.D.,
  Sr. VP of Antiviral & Immunotherapy
• Brian Cooley,
  Sr. VP of Lymphatic Drug Delivery BU Leader
• Dr. Shawn Sahebi Ph.D.,
  Sr. VP of Strategy & Analytics
• Dr. Mark R. Brunswick,
  Sr. VP of Regulatory Affairs
• Dr. Alexis Nahama,
  Sr. VP & Head of RTX Program
• Dr. Michael A. Royal,
  SVP & Chief Medical Officer
• Bill Farley,
  VP of Sales & Bus. Devel.
• Brian Sun,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Jane Ph D Hsiao,
  Director
• Management Ltd Abg Srne Ltd...,
  
• Douglas O Ebersole,
  Director
• Jeffrey Su,
  Executive VP and COO
• Kevin Herde,
  Executive VP and CFO
• William S Marth,
  Director
• Management Ltd Abg Srne Ltd...,
  
• George K Ng,
  See Remarks
• Patrick Chan Soon Shiong Fa...,
  
• Jerome B Zeldis,
  See Remarks
• David H Deming,
  Director
• Antonius Schuh,
  Chairman and CEO
• Steve Zaniboni,
  Director
• Curtis Lockshin,
  Director
• Donald R Scifres,
  10% owner
• Diane D S Tang Liu,
  Director
• Glenn L Halpryn,
  Director
• Charles P Rodi,
  VP, Research & Development
• Martina Molsbergen,
  VP, Business Development
• Dean Ferrigno,
  Chief Accounting Officer
• Pacific Med Tech (Bvi) Ltd ...,
  
• Management Ltd Abg Srne Ltd...,
  
• Management Ltd Abg Ii So Lt...,
  
• Jiong Shao,
  Chief Financial Officer
• Zhenwei Miao,
  Chief Technology Officer
• George Uy,
  Chief Commercial Officer
• Patrickmp 13 Ventures, Llc ...,
  
• Michael Scott Salka,
  Director
• Health, Inc. Opko,
  10% owner
• Mark Durand,
  Director
• Richard G Vincent,
  Chief Financial Officer
• Cam Gallagher,
  Director
• David Ritchie Webb,
  Director
• Ernst Guenter Afting,
  Director
• Vuong Trieu,
  CSO
• Elizabeth Czerepak,
  EVP & Chief Financial Officer
• Tammy Reilly,
  Director